Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2020; 09(03): 180-182
DOI: 10.1055/s-0040-1721177
Letter to the Editor

Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience

Vanita Noronha
1   Department of Medical Oncology, Tata Memorial Centre, HBNI, Mumbai, Maharashtra, India
,
Vikas T. Talreja
1   Department of Medical Oncology, Tata Memorial Centre, HBNI, Mumbai, Maharashtra, India
,
Vijay Patil
1   Department of Medical Oncology, Tata Memorial Centre, HBNI, Mumbai, Maharashtra, India
,
Amit Joshi
1   Department of Medical Oncology, Tata Memorial Centre, HBNI, Mumbai, Maharashtra, India
,
Nandini Menon
1   Department of Medical Oncology, Tata Memorial Centre, HBNI, Mumbai, Maharashtra, India
,
Abhishek Mahajan
2   Department of Radiology, Tata Memorial Centre, HBNI, Mumbai, Maharashtra, India
,
Amit Janu
2   Department of Radiology, Tata Memorial Centre, HBNI, Mumbai, Maharashtra, India
,
Kumar Prabhash
1   Department of Medical Oncology, Tata Memorial Centre, HBNI, Mumbai, Maharashtra, India
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints
Zoom Image
Vanita Noronha, MD, DM


Publication History

Article published online:
14 December 2020

© 2020. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Antonia SJ, Villegas A, Daniel D. et al. PACIFIC Investigators. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017; 377 (20) 1919-1929
    CrossrefPubMedGoogle Scholar
  • 2 Chakraborty S. A step-wise guide to performing survival analysis. Cancer Res Stat Treat 2018; 1: 41-5
    Google Scholar
  • 3 Goldstraw P, Chansky K, Crowley J. et al. International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016; 11 (01) 39-51
    CrossrefPubMedGoogle Scholar